Explore

Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics

Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics

Parabilis Medicines and Regeneron Pharmaceuticals Collaborate on Novel Therapeutics

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Regeneron and Parabilis Collaborate to Develop New Drug Class Targeting Undruggable Proteins

Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates

Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates

Parabilis and Regeneron Partner to Develop Novel Antibody-Helicon Conjugates

Regeneron drops after skin cancer treatment fails late-stage trial

Regeneron drops after skin cancer treatment fails late-stage trial

By Christy Santhosh May 18 (Reuters) - Regeneron's shares fell 12% in morning trade on Monday after the company's experimental treatment missed the main goal in a late-stage trial for patients with a type of skin cancer.

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Deal

Regeneron's Fianlimab Fails Phase 3 Melanoma Trial, Impacting Market Prospects

Regeneron's Fianlimab Fails Phase 3 Melanoma Trial, Impacting Market Prospects

Regeneron's Fianlimab Fails Phase 3 Melanoma Trial, Impacting Market Prospects

Akari Therapeutics Reports Increased Net Loss in Q1 2026 Amid Pre-Revenue Status

Akari Therapeutics Reports Increased Net Loss in Q1 2026 Amid Pre-Revenue Status

Akari Therapeutics Reports Increased Net Loss in Q1 2026 Amid Pre-Revenue Status

OpenBind Launches AI Model for Drug Discovery with Extensive Dataset

OpenBind Launches AI Model for Drug Discovery with Extensive Dataset

OpenBind Launches AI Model for Drug Discovery with Extensive Dataset

TRIANA Biomedicines Appoints Mohan Bala as COO, Expands Scientific Advisory Board

TRIANA Biomedicines Appoints Mohan Bala as COO, Expands Scientific Advisory Board

TRIANA Biomedicines Appoints Mohan Bala as COO, Expands Scientific Advisory Board

Incyte and Edison Scientific Collaborate to Enhance Drug Development with AI

Incyte and Edison Scientific Collaborate to Enhance Drug Development with AI

Incyte and Edison Scientific Collaborate to Enhance Drug Development with AI

OpenBind Introduces AI Model to Revolutionize Drug Discovery

OpenBind Introduces AI Model to Revolutionize Drug Discovery

OpenBind Introduces AI Model to Revolutionize Drug Discovery

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement

Bristol Myers Squibb Expands Oncology Pipeline with Lonza Licensing Agreement